SciClone Pharmaceuticals, a U.S.-based, China-focused specialty pharmaceutical company, markets its product portfolio of differentiated therapies for oncology, infectious diseases and cardiovascular, urological, respiratory and central nervous system disorders. The company’s ZADAXIN® is approved in more than 30 countries for the treatment of hepatitis B, hepatitis C and certain cancers. In addition, SCLN markets more than 15 products in China. For more information visit the company’s Web site at: www.sciclone.com.

Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital’s management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. For more information on Aegis Capital, visit www.aegiscapcorp.com.

Let us hear your thoughts below: